Skip to Content

Odefsey Approval History

FDA Approved: Yes (First approved March 1, 2016)
Brand name: Odefsey
Generic name: emtricitabine, rilpivirine and tenofovir alafenamide
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) is a fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), indicated as a complete regimen for the treatment of HIV-1 infection.

Development History and FDA Approval Process for Odefsey

DateArticle
Mar  1, 2016Approval FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection
Jul  1, 2015Gilead Submits NDA for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide